Last reviewed · How we verify
NCT03838913: WESIPNB
Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB)
trial in Bile Duct Neoplasms in 60 participants. Status unknown.
30 June 2019
Quick facts
| Lead sponsor | Fujian Provincial Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 15 February 2019 |
| Primary completion | 30 June 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across China |
Conditions studied
- Bile Duct Neoplasms — all drugs for Bile Duct Neoplasms →
- Intraductal Papillary Mucinous Neoplasm — all drugs for Intraductal Papillary Mucinous Neoplasm →
Sponsor
Fujian Provincial Hospital
Who can join
Adults 18 to 80, any sex, with Bile Duct Neoplasms or Intraductal Papillary Mucinous Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Intraductal papillary neoplasm of the bile duct (IPNB) is a distinct type of biliary tumor characterised with delicate fibrovascular stalks (papillary of villous) covered at biliary epithelium. The typical pathologic feature is dramatical dilation of affected bile ducts due to obstruction by mucin production. IPNB has a better prognosis than bile duct carcinoma, but the current proposed entity contains multiple definitions or categories, thus confused in pathology. Although mutations of several genes on IPNBs (such as GNAS, KRAS, APC, CTNNB1, and RNF43) identified in previous studies, there is still an unification at gene expression signature. This research trial will use whole exome sequencing and subsequent bioinformatic analysis in finding causative mutations in deoxyribonucleic acid (DNA) samples from IPNBs patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03838913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bile Duct Neoplasms
Currently open trials in the same condition.
- NCT05286814 — PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Color · Phase 2 · recruiting
- NCT05172310 — PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI · Phase 1 · recruiting
Other Fujian Provincial Hospital trials
Trials by the same sponsor.
- NCT07471763 — Prospective Lifespan Cohort of Myocardial Infarction · not yet recruiting
- NCT07290764 — Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic T · enrolling by invitation
- NCT07251114 — AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomi · NA · recruiting
- NCT06564506 — Electroacupuncture for Preventing Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty · NA · not yet recruiting
- NCT07380542 — Dynamic Magnesium Replacement Strategies and 28-Day Mortality in Non-Cardiac Critically Ill Patients With Hypomagnesemia · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03838913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Provincial Hospital
- Last refreshed: 12 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03838913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing